26/11/2025 22:11
|
Medical, Health & Aged Care
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancer
Sonrotoclax previously received Breakthrough Therapy...